Veronica Hood

About Veronica Hood

This author has not yet filled in any details.
So far Veronica Hood has created 16 blog entries.

Antisense oligonucleotide modulation of non-productive alternative splicing upregulates gene expression

By |2020-09-04T01:54:18-05:00August 13th, 2020|Categories: DSF Research Review|Tags: , , , |

Stoke Therapeutics published a paper in Nature Communications detailing the mechanism of action for their new TANGO (targeted augmentation of nuclear gene output) therapy that utilizes ASO (antisense oligonucleotide) technology. While the applications of this technology have been discussed in presentations and meetings, this is the first publication detailing how it was developed. Cells use [...]

Sustaining Telehealth Beyond the COVID-Era

By |2020-07-23T16:35:58-05:00July 24th, 2020|Categories: Decoding Dravet Blog|

I often reflect on the amount of time spent traveling to and from the numerous doctor and therapy appointments with my son over the years. Negotiating my work schedule, coordinating school and therapy schedules, packing medical equipment and medicines, loading my son and his wheelchair into the car, making the sometimes-long drives to the clinic, [...]

FINTEPLA FDA Approved

By |2020-07-15T13:04:24-05:00July 15th, 2020|Categories: Research / Treatments|

FINTEPLA® Receives FDS Approval for Treatment in Dravet Syndrome On June 25,2020, the FDA approved FINTEPLA® (fenfluramine) oral solution for the treatment of seizures in Dravet syndrome for patients 2 years and older. As part of the approval, the FDA required a black box warning on the medication. Additionally, the FDA requires the [...]

MONARCH Study Phase 1/2a

By |2020-07-15T13:08:01-05:00July 15th, 2020|Categories: Research / Treatments|

Stoke Therapeutics Launches MONARCH Study The MONARCH Study, conducted by Stoke Therapeutics, is currently enrolling for a Phase1/2a trial of STK-001. This new therapeutic medicine acts to specifically increase the number of healthy sodium channels (Nav1.1) that are impacted by mutations in SCN1A gene, the most common cause of Dravet syndrome. The study [...]

Stoke Therapeutics Launches MONARCH Study

By |2020-06-18T11:02:46-05:00June 18th, 2020|Categories: Decoding Dravet Blog|

The most common cause of Dravet syndrome is a genetic mutation in the SCN1A gene that results in a reduction in a type of sodium channel (Nav1.1) in the brain. A new type of medicine, STK-001, designed by Stoke Therapeutics increases healthy copies of the Nav1.1 sodium channel in pre-clinical animal and cell models. Stoke [...]

Soticlestat Trial Update

By |2020-06-15T14:39:57-05:00June 16th, 2020|Categories: Research / Treatments|

Clinical Trial Update Soticlestat (TAK-938/OV935) Ovid Therapeutics recently presented updates on their clinical trials of soticlestat (TAK-935/OV935) at the American Academy of Neurology virtual meeting for their adult DEE cohorts. Soticlestat targets the cholesterol pathway by inhibiting the enzyme CH24H (cholesterol 24-hydroxylase), which produces 24HC (24-hydroxycholesterol). When there is too much 24HC in [...]

Go to Top